Cabotegravir Sodium Crystal Forms for Phase Transition Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing forms of cabotegravir sodium are not thermodynamically stable, leading to potential phase transitions during pharmaceutical processing and storage, which can compromise safety and efficacy.
Innovation Solution
Development of novel crystalline forms, designated as Form B and Form C, which exhibit enhanced thermodynamic stability, characterized by specific powder X-ray diffraction patterns, and can be prepared through solvent slurry methods to minimize phase transitions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional preparation methods are used to produce cabotegravir sodium, then the compound can be obtained as a solid form, but it lacks thermodynamic stability and undergoes phase transitions during storage and processing
Solution Approach 1:
The patent applies parameter changes by systematically varying preparation conditions including solvent types (aqueous vs. organic), temperatures (room temperature vs. elevated temperatures), concentrations, and pH levels to induce formation of thermodynamically stable crystalline forms (Forms B and C) with different lattice structures that resist phase transitions
Solution Approach 2:
The patent utilizes phase transition principles by controlling the transformation from metastable Form A to stable crystalline Forms B and C through controlled crystallization processes, leveraging solubility differences and thermodynamic driving forces to achieve stable solid forms that maintain their structure during storage
2Productivity
If rapid preparation methods are used, then production efficiency is improved, but phase transitions and polymorphic conversions may occur during processing
Solution Approach 1:
The patent applies preliminary action by pre-establishing stable crystalline forms through controlled crystallization before subsequent processing steps, ensuring that the material is already in its most stable state when encountered with formulation conditions, thereby preventing later phase transitions
Solution Approach 2:
The patent uses intermediary substances including specific solvents (water, organic solvents), additives, and formulation excipients as mediators that stabilize the crystalline structure during processing, preventing polymorphic conversions while allowing efficient manufacturing through controlled environment
3Ease of operation
If existing solid forms are used, then the compound is easy to handle, but dissolution profile and shelf-life are compromised due to lack of stability
Solution Approach 1:
The patent applies composite material principles by creating stable crystalline forms with optimized lattice structures that combine ease of handling with enhanced stability, and by formulating compositions that incorporate stabilizing excipients and protective coatings to maintain form integrity throughout shelf-life
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ensures reliable safety and efficacy of pharmaceutical compositions by maintaining stability during manufacturing and storage, reducing the risk of polymorphic conversions and amorphization.
Implementation Method 1
Different solid state forms of an active pharmaceutical ingredient often possess different properties. Differences in the physicochemical properties of solid state forms can be important for the improvement of pharmaceutical compositions
Data Source
AI summary
The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.